You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PDL1 antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer, Pancreatic Cancer, Metastatic Cancer Trial in Lyon, Toulouse (Pexidartinib, Durvalumab)

Completed
  • Colorectal Cancer
  • +3 more
  • Lyon, France
  • +1 more
Sep 2, 2021

Skin Health and Quality of Life in Patients Receiving

Not yet recruiting
  • Lung Cancer
  • +7 more
  • EQ-5D-5L questionnaire
  • +2 more
  • Roma, Italy
    Roberto Iacovelli
May 17, 2023

Advanced Tumors, Lymphoma, Metastatic Tumors Trial in Changchun, Jinan (HLX301)

Recruiting
  • Advanced Tumors
  • +2 more
  • Changchun, Jilin, China
  • +1 more
Jul 12, 2022

Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

Not yet recruiting
  • Cervical Cancer
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023

SCLC,Extensive Stage Trial in Changchun (AK104 IV infusion;Chiauranib oral)

Not yet recruiting
  • SCLC,Extensive Stage
  • AK104 IV infusion；Chiauranib oral
  • Changchun, Jilin, China
    Jilin Province Cancer Hospital
Aug 16, 2022

T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in London (Avelumab)

Completed
  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory
  • London, United Kingdom
    University College London Hospital
Oct 1, 2021

Locally Advanced or Metastatic Solid Tumors, NSCLC Trial in Australia (HLX301)

Recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • Non-small Cell Lung Cancer
  • Blacktown, New South Wales, Australia
  • +4 more
May 25, 2022

Solid Tumor Trial in Richmond (Stereotactic radiotherapy, Biological: humanized anti-PD-1 mAb, Biological: humanized anti-PD-L1

Completed
Has Results
  • Solid Tumor
  • Stereotactic radiotherapy
  • +2 more
  • Richmond, Virginia
    Virginia Commonwealth University/Massey Cancer Center
Dec 20, 2021

Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma Trial in Rochester (Anti-PD-L1 Monoclonal Antibody

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +3 more
  • Anti-PD-L1 Monoclonal Antibody IMC-001
  • Punch Biopsy
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8

Recruiting
  • Stage III Merkel Cell Carcinoma AJCC v8
  • +2 more
  • Orange, California
  • +10 more
Jan 30, 2023

PDL1 In Primary Colorectal Carcinoma and Its Prognostic Impact

Not yet recruiting
  • PDL1- Colorectal Carcinoma
    • (no location specified)
    Jan 11, 2023

    Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma Trial in Belgium, United States (Bapotulimab (BAY1905254),

    Active, not recruiting
    • Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
    • Bapotulimab (BAY1905254)
    • Bapotulimab (BAY1905254) + Pembrolizumab
    • Tucson, Arizona
    • +7 more
    Jan 12, 2023

    Metastatic Solid Tumors, NSCLC, Melanoma Trial in United States (INBRX-105 - PDL1x41BB antibody, Pembrolizumab)

    Recruiting
    • Metastatic Solid Tumors
    • +7 more
    • Scottsdale, Arizona
    • +12 more
    Jan 26, 2023

    Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)

    Active, not recruiting
    • Melanoma
    • +7 more
    • Scottsdale, Arizona
    • +36 more
    Dec 22, 2022

    Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody

    Active, not recruiting
    • Recurrent Acute Myeloid Leukemia
    • Refractory Acute Myeloid Leukemia
    • Anti-OX40 Agonist Monoclonal Antibody PF-04518600
    • +6 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 25, 2022

    Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT

    Recruiting
    • Lung Cancer Stage III
    • Lung Cancer Stage IV
      • Brest, France
        Chu Brest
      Aug 16, 2023

      HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With

      Not yet recruiting
      • Gastric Cancer
      • Observational
      • (no location specified)
      Dec 13, 2022

      Solid Tumor Malignancy, Hematologic Malignancy, Leukemia Trial run by the NCI (mrna 1273 injection)

      Recruiting
      • Solid Tumor Malignancy
      • +4 more
      • mRNA-1273
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 14, 2023

      NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

      Not yet recruiting
      • Non-small Cell Lung Cancer
      • +4 more
      • MK-2870
      • +2 more
      • (no location specified)
      Sep 15, 2023

      Multiple Myeloma Trial (Bone marow biopsy and aspiration, biochemical and heamatological tests)

      Not yet recruiting
      • Multiple Myeloma
      • Bone marow biopsy and aspiration
      • biochemical and heamatological tests
      • (no location specified)
      Aug 9, 2023

      Lung Cancer, Liver Cancer, Colorectal Cancer Trial in Guangzhou (ipilimumab +pembrolizumab +durvalumab)

      Recruiting
      • Lung Cancer
      • +10 more
      • ipilimumab +pembrolizumab +durvalumab
      • Guangzhou, Guangdong, China
        The Second Affiliated Hospital of Guangzhou Medical University
      Jan 10, 2022

      Advanced Solid Tumor, NSCLC Trial in Taiwan, United States (NM21-1480)

      Recruiting
      • Advanced Solid Tumor
      • Non-small Cell Lung Cancer
      • NM21-1480
      • Pittsburgh, Pennsylvania
      • +3 more
      May 18, 2021

      Advanced Gastroesophageal Adenocarcinoma, First-line Therapy, PDL1 CPS < 5 Trial (CAPOX combined with bevacizumab and

      Not yet recruiting
      • Advanced Gastroesophageal Adenocarcinoma
      • +2 more
      • CAPOX combined with bevacizumab and Tislelizumab
      • (no location specified)
      Mar 17, 2022

      NSCLC Trial (Phase I - Mirdametinib - Level 1, Phase II - Mirdametinib, Phase I - Mirdametinib - Level 2)

      Not yet recruiting
      • Non-Small Cell Lung Cancer
      • Phase I - Mirdametinib - Level 1
      • +4 more
      • (no location specified)
      Jul 7, 2023

      Primary Hepatocellular Carcinoma Trial (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for

      Not yet recruiting
      • Primary Hepatocellular Carcinoma
      • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
      • camrelizumab for Injection
      • (no location specified)
      Nov 13, 2023